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Lithium for prevention of mood episodes in
bipolar disorders: systematic review and
meta-analysis
Emanuel Severus1*†, Matthew J Taylor2†, Cathrin Sauer1, Andrea Pfennig1, Philipp Ritter1, Michael Bauer1
and John R Geddes3
Abstract
Background: In a previous meta-analysis of randomized controlled trials comparing lithium with placebo as a
long-term treatment in bipolar disorders, we observed a clear preventative effect for manic episodes; however, the
effect was equivocal for depressive episodes. Since then, the evidence base has grown further. In this update, we
furthermore present the data on efficacy of lithium in comparison to alternative drug treatments. In addition, we
analyze the data comparing lithium with placebo and other treatments regarding drop-outs due to reasons other
than a mood episode and completion of study (no mood episode and no drop-out to reasons other than a
mood episode).
Methods: Randomized controlled trials (RCTs) were sought comparing lithium with placebo and lithium with an
alternative treatment in bipolar disorders where the stated intent of treatment was prevention of mood episodes.
To this purpose, the Cochrane Central Register of Controlled Trials (CENTRAL) was searched. Reference lists of
relevant papers and major textbooks of mood disorders were examined. Authors, other experts in the field, and
pharmaceutical companies were contacted for knowledge of suitable trials, published or unpublished.
Results: For the comparison of lithium with placebo, seven trials (1,580 participants) were included. Lithium was
more effective than placebo in preventing overall mood episodes (random effects RR 0.66, 95% CI 0.53 to 0.82),
manic episodes (random effects RR 0.52, 95% CI 0.38 to 0.71), and, dependent on the type of analyses applied,
depressive episodes (random effects RR 0.78, 95% CI 0.59 to 1.03; fixed effect RR 0.73, 95% CI 0.60 to 0.88). Lithium
was inferior to placebo in leading to drop-outs for reasons other than a mood episode (random effects RR 1.33,
95% CI 1.07 to 1.65) but superior to placebo on study completion (random effects RR 1.69, 95% CI 1.12 to 2.55).
For the comparison of lithium with anticonvulsants, seven trials were included (n = 1,305). In prevention of manic
episodes, lithium showed superiority compared to anticonvulsants (random effects RR 0.66, 95% CI 0.44 to 1.00).
However, there was no significant difference regarding prevention of overall mood episodes, depressive episodes,
dropping-out to reasons other than a mood episode, or study completion.
Conclusions: The evidence base for lithium in the long-term treatment of bipolar disorders has strengthened. With
no other drug available having such ample and consistent evidence for its efficacy lithium remains the most valuable
treatment option in this indication.
Keywords: Lithium; Placebo; Anticonvulsants; Systematic review; Randomized controlled trial; Meta-analysis;
Bipolar disorders; Long-term treatment
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Background
Rationale
Bipolar disorders are common and disabling and have a
tendency to recur. The defining features of this group of
disorders are disturbances of mood with episodes of
depression (lowered mood) and mania (elevated/irritable
mood and increased energy). Most episodes of illness
recover over time and with treatment, but there is a
marked tendency for these disorders to be recurrent
(Geddes and Miklowitz 2013). It has been estimated that
at least 80% who have an episode of mania will have one or
more recurrences (NIMH/NIH Consensus Development
Conference statement 1985; 2002; Quitkin et al. 1976). In
addition, subclinical symptoms may persist and become
chronic.
Long-term treatment to prevent mood episodes (relapse
during continuation treatment as well as recurrences
during maintenance/prophylactic treatment) is there-
fore of vital importance in the management of bipolar
disorders. That lithium can prevent mood episodes has
been recognized since the 1960s (Abou-Saleh and Coppen
1986). Since then, lithium has become a mainstay of
preventative treatment in bipolar disorders, as well as in
unipolar depression (Cipriani et al. 2006). Furthermore,
lithium has been recommended for the treatment of acute
mania and for the augmentation of antidepressants in
unipolar depression (Katona 1995; Bauer et al. 2014). Its
effectiveness as an antidepressant when used alone has
been disputed (Bauer et al. 2006; Bschor et al. 2013). This
review focuses on the use of lithium to prevent mood
episodes in bipolar disorders.
Lithium is widely used in clinical practice in the long-
term treatment of affective disorders (Kessing et al.
2011; Kessing et al. 2012). Its use has been considered well
established (Licht 2012; Crossley et al. 2006), although
some have seriously questioned its efficacy (Blackwell and
Shepherd 1968; Moncrieff 1997). Abrupt discontinuation/
lowering of long-term lithium treatment in bipolar pa-
tients is known to precipitate episodes of affective illness
(Goodwin 1994; Suppes et al. 1991), in particular if serum
levels abruptly drop of more than 0.2 mmol/L (Severus
et al. 2008). The early randomized controlled trials that
established the use of lithium therapy have been criticized
as several of them were of a discontinuation design. It has
been suggested that the considerable beneficial effect of
lithium found in these studies was due to such a discon-
tinuation effect (Moncrieff 1997).
In the latest previous systematic review and meta-
analysis which dates back to 2004 (Geddes et al. 2004),
we found evidence from randomized controlled trials
including 770 participants that lithium treatment reduces
the risk of mood episodes in bipolar disorders. The pre-
ventive effect was clear for manic episodes, although it was
equivocal for depressive episodes. Since then, the evidence
base has substantially grown further, particularly through
lithium’s use as active comparator in trials of alternative
treatments. The time is therefore ripe for a reassessment of
the evidence for lithium’s efficacy in relapse/recurrence
prevention of bipolar disorders. In addition, the previous
meta-analysis did not include data on discontinuation for
reasons other than a mood episode though differences
between lithium and placebo/active comparator in this
issue may bias the data on efficacy and vice versa.
Objectives
Here, we aim to determine the efficacy of lithium therapy
in preventing episodes of mood disorders in persons with
bipolar disorders and to assess whether it is effective in
the prevention of both manic and depressive episodes. In
addition, we present data on study withdrawals - ‘drop-
outs’ - due to reasons other than a mood episode (e.g. side
effects) and number of individuals completing the study
for lithium compared to placebo/alternative treatment. In
addition to the methodological importance of study with-
drawal (Licht and Severus 2014), scrutiny of withdrawal is
important to provide a realistic idea on the effectiveness
of lithium in real-world clinical practice: good tolerability
is vital for long-term adherence which, in turn, is a pre-
requisite for lithium to realize its potential to prevent
mood episodes and instability in bipolar disorders (Malhi
et al. 2012).
Methods
Eligibility criteria
Randomized controlled parallel-group studies published
in English or German were considered. Males and females
aged 16+ with a diagnosis of bipolar disorders, in partial
or full remission, were included. Studies of participants
with mixed diagnoses of mood disorders were included
where those participants with bipolar disorders were sep-
arately randomized between treatments.
Types of interventions
 Studies included were those comparing lithium
with placebo and those comparing lithium with an
alternative treatment (anticonvulsant or atypical
antipsychotic) to prevent mood episodes where
follow-up was for at least 3 months.
 For the analyses comparing lithium with either an
anticonvulsant or antipsychotic, we only included
those comparisons where there were at least two
studies for each specific drug as a smaller number
was considered insufficient for estimating the
between-studies variance.
 To increase the likelihood of comparability between
intervention groups, we excluded small studies
(n < 50 per treatment arm) where key data
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regarding potentially outcome-relevant clinical
variables between the intervention groups
at baseline were missing (i.e. age, sex,
severity of the illness (history and at baseline))
(Pfennig et al. 2012).
 Discontinuation studies (in which patients who had
been in remission on lithium for at least 2
consecutive months were selected, then randomly
assigned to continued lithium treatment or
placebo/alternative treatment substitution) were
excluded from the analyses.
 We excluded trials that were confounded by
adjunctive treatments i.e. when lithium was
combined with another treatment such as an
antidepressant or anticonvulsant. However, in
factorial trials of lithium, placebo, and another active
comparator, we included both the lithium versus
placebo and the lithium versus active comparator
comparison because the factorial design allows an
unconfounded comparison.
Types of outcome measures
We used the definition of relapse/recurrence as defined by
the authors of the original trials (Table 1). We extracted
and analyzed data on the total number of recurrences/
relapses as well as the number of manic/hypomanic
episodes and the number of depressive episodes. We ex-
tracted and analyzed the number of participants dropping
out of treatment during the study period for reasons other
than a mood episode, as this number is possibly reflecting,
at least in part, tolerability or acceptability issues. We
also extracted and analyzed the number of individuals
completing a study which is defined by the number
of individuals randomized to either lithium or placebo/
alternative treatment minus the number of individuals
who developed a mood episode minus the number of
individuals who dropped out of the study for reasons
other than a mood episode.
Information sources and search
1). Electronic databases
The Cochrane Central Register of Controlled Trials
(CENTRAL) were searched to April 2013 using the
following search terms: (LITHIUM OR CAMCOLIT
OR CARBOLITH OR DUROLITH OR ESKALITH
OR LICARBIUM OR LISKONUM OR LITAREX
OR LITHANE OR LITHOCARB OR LITHIZINE
OR LITHONATE OR LITHOTABS OR
MANIALITH OR PHASAL OR PRIADEL OR
QUILONORM OR QUILONUM OR LI-LIQUID)
and (bipolar OR mania OR manic). CENTRAL
includes relevant records retrieved from MEDLINE,
Embase, PsycINFO, Cochrane Review Group
registers incorporating additional databases, and
hand-searching activities.
2). Reference checking
The reference lists of all identified randomized
controlled trials, other relevant papers, and major
textbooks on mood disorders were checked.
3).Hand searching
The journals Lithium (1990 to 1994) and Lithium
Therapy Monographs (1987 to 1991) were
hand-searched.
4). Personal communication
The authors of randomized controlled trials
included in the review and other recognized experts
in the field were contacted and asked if they had
knowledge of any other studies, published or
unpublished, relevant to the review. Pharmaceutical
companies marketing lithium products were
requested to provide relevant published and
unpublished data. Following the publication of the
first version of this review, we kept in contact with
identified active trial lists and companies to identify
any emerging trials. For one study (Licht et al. 2010),
it was possible to add the split data for manic and
depressive episodes (after 2 years of follow-up) to the
review/meta-analysis after consulting the author.
Study selection and data collection process
Studies generated by the search strategies were checked to
ensure they met the previously defined inclusion criteria.
Two reviewers independently extracted data concerning
participant characteristics, intervention details (including
participants’ lithium exposure immediately preceding the
trial), and outcome measures from the included studies.
Any disagreements were resolved by consensus.
Risk of bias in individual studies
Quality assessment: the methodological quality of the
included studies was assessed according to the Cochrane
criteria for quality assessment (Higgins et al. 2003). On
this basis, studies were given a rating of A (adequate
randomization and concealment), B (unclear), and C (in-
adequate). Other aspects of methodological quality that
have been shown to be related to validity were assessed
by two reviewers independently. In cases where inad-
equate details of randomization and other methodologies
were provided in published papers, the authors were
contacted to obtain further information. Quality ratings
were revised in several cases on the basis of information
received from authors (Table 1).
Summary measures and synthesis of results
Data analysis: data were analyzed using RevMan 5.1
software (The Cochrane Collaboration 2014) and R
(R Development Core Team. R 2005). Heterogeneity
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Table 1 Characteristics of studies included in a meta-analysis of trials assessing the effectiveness of lithium for prevention of mood episodes in bipolar disorders
Study Year Comparator Design Participants Interventions
(with levels)
Definition of
relapse/recurrence
Quality (rating) Previous lithium/
comparator use
Lithium/comparator
serum level achieved
Prien 1973 1973 Placebo Random
assignment,
2-year follow-up
Patients with manic
depressive disorder,
manic type (n = 205),
age 17 to 60 years;
most recent episode:
manic
Lithium (0.5 to
1.4 mEq/l);
placebo
Emergent manic or
depressive attack
measured on Global
Affective Scale
requiring hospitalization
(severe relapse) or
supplementary
medication (moderate
relapse); combined
moderate and severe
relapse rates used
Allocation concealment
unclear (B); participants
and clinical raters
blinded to treatment
allocation; treating
physician not blinded (A)
Following remission
of the acute manic
episode and prior to
discharge (time of
randomization) patients
were stabilized on lithium
(0.5 to 1.4 mEq/l)
Median serum lithium
level 0.7 mEq/l
Kane 1982 1982 Placebo Random
assignment,
up to 2-year
follow-up
Patients with
bipolar II disorder
(Research Diagnostic
Criteria) (n = 22),
age 18 to 65 years;
patients had been
euthymic for 6
months prior to
entry into the study
Lithium (0.8 to
1.2 mEq/l);
imipramine
(100 to 150 mg
per day);
lithium plus
imipramine;
placebo
Emergent mood
episode meeting
Research Diagnostic
Criteria for major
depressive disorder
for 1 week, minor
depressive disorder for
4 weeks, manic episode
for any duration, or
hypomanic episode
for 1 week
Allocation concealment
unclear (B); patients and
physicians blinded to
treatment allocation (A)
Patients had been on
open uncontrolled
continuation treatment
for 6 months (except for
the last 6 weeks
(open treatment with
imipramine)) before they
were randomly assigned
to treatment condition
Not available
Greil 1997 1997 Carbamazepine Random
assignment,
2.5 years
observation
period, primary
aim was to
assess efficacy
of carbamazepine
Patients with
current episode
of bipolar affective
disorder (ICD-9: 296.2,
296.3, 296.4) (n = 144),
no preventive
treatment immediately
before current episode,
age 18 to 65 years
Lithium (0.6 to
0.8 mmol/l);
carbamazepine
(4 to 12 μg/ml)
Recurrence, i.e. rating
of psychopathology
of 5 (=recurrence) or
6 (=extremely severe
recurrence)
corresponding to the
recurrence of an
affective episode in line
with the Research
Diagnostic Criteria
Non-blind design,
randomization
procedure by Efron
(1971) (A); Allocation
concealment adequate
(A): central allocation
through coordinating
study centre, treatment
group allocation by
phone at the moment
of randomization
Stabilization phase:
psychotropic medication
according to the free
decision of the treating
physician was gradually
reduced and, if possible,
discontinued before
randomization; 84%
never had received
prophylactic treatment
before
0.63 ± 0.12 mmol/l
Bowden
2000
2000 Placebo,
valproate
Random
assignment,
1-year follow-up,
primary aim was
to assess efficacy
of divalproex
Patients with
bipolar I disorder
(DSM-III-R) with
index manic episode
according to Structured
Clinical Interview for
DSM-III-R (n=372),
those with high suicide
risk excluded, age
18-75 years
Lithium (0.8 to
1.2 mEq/l);
divalproex (71
to 125 ug/ml);
placebo
Emergent manic
episode (Mania Rating
Scale score of 16 or
more or requiring
hospitalization) or
depressive episode
(requiring
antidepressant use
or premature study
withdrawal)
Allocation concealment
unclear (B); patients,
clinicians, and outcome
assessors blinded to
treatment allocation (A)
Before randomization,
117/372 were treated
with open-label dival
proex, 124 with lithium,
50 with both drugs, 81
with neither drug;
lithium as well as
divalproex were
gradually reduced
and withdrawn during
the first 2 weeks of
maintenance treatment
Mean (SD) serum
lithium concentration
by day 30: 1.0 ± 0.48
mEq/l; mean (SD)
valproate concentration
by day 30: 84.8 ± 29.9
ug/ml
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Table 1 Characteristics of studies included in a meta-analysis of trials assessing the effectiveness of lithium for prevention of mood episodes in bipolar disorders
(Continued)
Bowden
2003
2003 Placebo,
lamotrigine
Random
assignment,
1-year follow-up,
primary aim was
to assess efficacy
of lamotrigine
Patients with bipolar I
disorder recently
recovered from a
manic or hypomanic
episode (DSM-IV)
(n = 175), age ≥18
years
Lithium (0.8 to
1.1 mEq/l);
placebo;
lamotrigine
(100 to 400 mg
per day)
Intervention (additional
medication or ECT)
required for any mood
episode; secondary
outcomes subdivided
by type of mood episode
(manic/hypomanic/mixed
or depressive)
Allocation concealment
unclear (B); patients,
clinicians, and outcome
assessors blinded to
treatment allocation (A)
Majority of participants
had a prior history of
lithium use (31/46: 70%
in lithium group; 42/69:
67% in placebo group;
38/58: 72% in
lamotrigine group). 18%
of participants during
the initial part of the 8-
to 16-week open-label
phase received lithium,
the dosage of which
was tapered over at
least 3 weeks and
discontinued a minimum
of 1 week before they
entered the double-blind
phase of the study. All
participants received
open-label lamotrigine
during the open-label
phase (target dosage
200 mg/d; minimum
100 mg/d). Concomitant
psychotropic medications
were permitted during
the open-label phase as
needed to treat an
ongoing manic or
hypomanic episode but
were discontinued a
minimum of 1 to 2
weeks before entry into
the double-blind phase.
Not available
Calabrese
2003
2003 Placebo,
lamotrigine
Random
assignment,
1-year follow-up,
primary aim was
to assess efficacy
of lamotrigine
Patients with bipolar
I disorder recently
recovered from a
major depressive
episode according
to DSM-IV (n = 463),
age ≥18 years
Lithium (0.8 to
1.1 mEq/l);
placebo;
lamotrigine
(50 to 400 mg
per day)
Intervention (additional
medication or ECT)
required for any mood
episode; secondary
outcomes subdivided
by type of mood episode
(manic/hypomanic/mixed
or depressive)
Allocation concealment
unclear (B); patients,
clinicians, and outcome
assessors blinded to
treatment allocation (A)
Majority of participants
had a prior history of
lithium use (57% to 62%
of patients had received
prior lithium treatment
at some point, with 67%
to 72% of these patients
having achieved good
clinical response and
80% to 85% having
tolerated such prior
treatment). 20% of
participants in open
label run in received
lithium, dosage tapered
over at least 3 weeks
and discontinued
Steady-state mean ±
SD serum levels of
0.8 ± 0.3 mEq/l
Severus
et
al.InternationalJournalof
Bipolar
D
isorders
2014,2:15
Page
5
of
17
http://w
w
w
.journalbipolardisorders.com
/content/2/1/15
Table 1 Characteristics of studies included in a meta-analysis of trials assessing the effectiveness of lithium for prevention of mood episodes in bipolar disorders
(Continued)
a minimum of 1 week
prior to entering the
double-blind phase; any
psychotropic medication
permitted during 8- to
16- week open-label
phase; all patients
received lamotrigine
(target dosage 200 mg/d;
minimum 100 mg/d) as
adjunctive therapy or
monotherapy; all
psychotropic medication
other than lamotrigine
were discontinued at
least 7 days prior to
randomization
Hartong
2003
2003 Carbamazepine Random
assignment,
2-year study
Patients with bipolar
disorder (DSM-III-R)
with at least two
episodes during
the last 3 years,
recovered from
last episode
(n = 94), age ≥18
years
Lithium (0.6
to 1.0 mmol/l);
carbamazepine
(6 to 10 mg/l))
Recurrence of an
episode of (hypo)mania
or major depression
according to
DSM-III-R criteria
Allocation concealment
adequate: pharmacy-
controlled block
randomization (A);
double dummy design,
double blind (A)
Total lithium/
carbamazepine
treatment during
lifetime ≤6 months;
at randomization,
no patient received
antidepressants,
antipsychotics, or
benzodiazepines.
Lithium level mean
(SD): 0.75 (0.18) mmol/l;
carbamazepine level
mean (SD): 6.8 (1.2) mg/l
Geddes
2010
2010 Valproate Random
assignment,
24-month
follow-up,
primary aim was
to assess efficacy
of lithium-valproate
combination
therapy
Patients with bipolar
I disorder on the basis
of a previous episode
of mania meeting
DSM-IV criteria (n = 330),
age ≥16 years; most
recent episodes 52%
mania, 34% depression,
12% mixed, 3% cycling
Lithium (0.4
to 1.0 mmol/l);
valproate (750
to 1,250 mg)
Initiation of new
intervention for an
emergent mood
episode, including
drug treatment or
admission to hospital
Randomization
computerized,
minimization; allocation
concealment adequate:
central allocation via
telephone (A);
investigators and
participants informed
of treatment allocation,
trial management team
masked to treatment
assignment (A)
Before randomization
active run-in of 4 to 8
weeks: all patients re
ceived lithium and val
proate (lithium serum
level 0.4 to 1.0 mmol/l;
valproate dose at least
750 mg or valproic acid
serum concentration at
least 50 μg/ml)
Not available
Licht 2010 2010 Lamotrigine Random
assignment, up
to 5.8-year
follow-up,
primary aim was
to assess efficacy
of lamotrigine
Patients with
bipolar I disorder
according to DSM-IV
with at least two
episodes within the
last 5 years
(n = 155) recruited
during or in the
aftermath of an
Lithium (0.5
to 1.0 mmol/l);
lamotrigine
(up-titrated to
400 mg/day)
Psychotropic treatment
(in addition to study
drug and benzodiazepines)
and/or hospitalization
still required at month
6 after randomization;
psychotropic treatment
(in addition to study
drug and benzodiazepines)
Allocation concealment
adequate: central
allocation; computer-
generated
randomization plan,
block randomization (A)
Prior lithium prophylaxis:
13 (17%) in lamotrigine
group, 15 (19%) in
lithium group; patients
receiving lithium until
randomization and
assigned to lamotrigine
group: lithium was
tapered off over 1 to
Serum lithium level:
mean 0.69 mmol/l
(SD = 0.20); lamotrigine
dose: mean 379 mg
(SD = 66) (serum level
22.5 (12.7) μmol/l)
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Table 1 Characteristics of studies included in a meta-analysis of trials assessing the effectiveness of lithium for prevention of mood episodes in bipolar disorders
(Continued)
index episode,
age ≥18 years;
index episode either
depression (51%),
mania (41%), or
mixed mania (8%)
according to the
Cincinnati criteria,
onset within the
last year prior to
randomization
during at least 1 week
and/or hospitalization
during at least 1 week
still required after month 6
(after randomization)
3 months; patients
receiving lamotrigine
until randomization and
assigned to lithium
group: discontinuation
of lamotrigine at
randomization.
Additional antipsychotic
or antidepressant drugs
were allowed in the
first 6 months after
randomization,
investigators were
encouraged to achieve
monotherapy at month
6. Benzodiazepines
allowed throughout
the study.
Amsterdam
2010
2010 Placebo,
fluoxetine
Random
assignment, up
to 1-year
follow-up
Patients with bipolar
II disorder (n = 81)
recently recovered
from depressive
episode with
fluoxetine treatment,
age 19 to 67 years
Lithium (0.5
to 1.5 mEq/l);
fluoxetine (10
to 40 mg per
day); placebo
Depressive relapse
defined as HAMD
score of 14 or more and
meeting diagnostic
criteria for major depressive
episode. Hypomanic
episode defined by DSM-IV
criteria
Allocation concealment
unclear (B); patients,
clinicians, and outcome
assessors blinded to
treatment allocation (A)
Initial fluoxetine
monotherapy was
administered on the
basis of response and
tolerability. Patients who
had a final HAM-D score ≤
8 by week 12 of treatment
were randomly assigned
to different treatment
arms. Patients assigned to
fluoxetine group who
previously took >40
mg/day of fluoxetine:
dosage reduced to
40 mg/day; previously
≤ 40 mg/day: dosage
maintained; patients
assigned to lithium
group: fluoxetine
therapy discontinued.
Lithium therapy initiated
at 600 mg/day for 1
week, increased to
900 mg/day in week 2,
continued until serum
level of 0.5 to 1.5 mEq/l
achieved by week 4.
Mean average serum
lithium level was 0.69
mmol/liter (SD = 0.27),
mean average
maximum fluoxetine
dose 34.3 mg/day
(SD = 7.9)
Weisler
et al. 2011
2011 Placebo,
quetiapine
Random
assignment,
up to 2-year
follow-up
Patients with bipolar
I disorder (DSM-IV)
recently recovered
from a manic
(53.6%), depressive
Lithium (0.6 to
1.2 mEq/l);
quetiapine
(300 to 800 mg
per day); placebo
Emergent mood event
requiring medication or
hospitalization, YMRS or
MADRS 20 or more
on two consecutive
Allocation by
centralized
randomization and
drug allocation system
(A); patients, clinicians,
All patients received
open-label quetiapine
(300 - 800 mg/d) for 4-24
weeks. Patients achieving
stabilization on quetiapine
Mean (SD) median
serum concentration
was 0.63 (0.45) mEq/l;
mean (SD) median
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Table 1 Characteristics of studies included in a meta-analysis of trials assessing the effectiveness of lithium for prevention of mood episodes in bipolar disorders
(Continued)
(28%) or mixed
episode (18.4%)
(n = 1,172),
age ≥18 years
assessments,
discontinuation attributed
to mood event by
investigator
and outcome assessors
blinded to treatment
allocation (A)
were randomized to
different treatment arms.
Replacement of quetiapine
tablets used during
prerandomization
phase started on day 1
and was completed by 2
weeks. Known intolerance
or lack of response to
lithium was an exclusion
criterion
quetiapine dose
546 (173) mg
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between studies was assessed using the I2 statistic
(Higgins et al. 2003).
For binary efficacy outcomes, random effects
(DerSimonian and Laird 1986) and fixed effect (Greenland
and Robins 1985; Mantel and Haenszel 1959) risk ratios
with 95% confidence intervals were calculated. Fixed effect
analysis assumes the included studies to be functionally
identical and the underlying treatment effect size to be the
same in all studies. Random effects analysis assumes a
range of treatment effects and incorporates inter-study
variation into the pooled estimate. Therefore, we primarily
used the random effects model for our analyses. Neverthe-
less, in order to allow an estimation of the sensitivity of
the results to the choice of method, we always present
both sets of results. In addition, it is also common to re-
port fixed effects if the statistical test for heterogeneity in-
dicates relative homogeneity.
Where possible, we intended to use intention-to-treat
(ITT) data for the primary efficacy analyses. Where ITT
data were not available, we used endpoint data for trial
completers. Data from trials including both unipolar and
bipolar participants were only included in the respective
analysis if the two diagnostic groups had been randomized
separately.
Results
Study selection
Using our search strategy, we identified 806 studies, which
were subsequently screened. As a result, 731 records were
excluded, while the remaining 75 records were assessed
for eligibility (full-text articles). For a variety of reasons, as
detailed in Figure 1, 11 studies could be included for
qualitative and quantitative analysis (Moher et al. 2009).
Figure 1 PRISMA flowchart of the inclusion procedure.
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Study characteristics
Lithium versus placebo
Seven trials were included in this part of the updated
review. Six trials included only bipolar participants
(Prien et al. 1973; Bowden et al. 2000; Calabrese et al.
2003; Bowden et al. 2003; Amsterdam and Shults 2010;
Weisler et al. 2011). One trial reported on groups with
bipolar disorders and unipolar disorders that were
randomized separately (Kane et al. 1982). Two trials
were similar in design except that one recruited patients
who had recently recovered from a depressive episode
(Calabrese et al. 2003) and the other recruited patients
who had recently recovered from a manic or hypomanic
episode (Bowden et al. 2003).
Several trials included a third active treatment arm. In
one study (Bowden et al. 2000), the third group received
divalproex, a form of valproic acid; in two studies
(Calabrese et al. 2003; Bowden et al. 2003), a third arm
were allocated to lamotrigine. These three studies were
also included in the lithium versus anticonvulsant analysis.
One study included a fluoxetine arm (Amsterdam and
Shults 2010) and the final study included a quetiapine arm
(Weisler et al. 2011). One trial had a factorial design in
which patients were allocated to lithium, placebo, imi-
pramine, or lithium + imipramine (Kane et al. 1982). As
stated in the ‘Methods’ section, we had decided to exclude
treatment groups that were confounded by adjunctive
antidepressant treatment, therefore we excluded the lith-
ium + imipramine and the placebo + imipramine groups
from the analyses.
Lithium versus anticonvulsant
Seven trials were included in this analysis, including the
three studies from the lithium versus placebo analysis with
an anticonvulsant as a third treatment arm (Bowden et al.
2000; Calabrese et al. 2003; Bowden et al. 2003).
Two studies compared lithium to carbamazepine (Greil
et al. 1997; Hartong et al. 2003), three to lamotrigine
(Licht et al. 2010; Calabrese et al. 2003; Bowden et al.
2003), and two studies to valproate (Bowden et al. 2000;
Geddes et al. 2010). All trials included bipolar patients
exclusively.
Figure 3 Prevention of depressive/manic episodes in bipolar disorders patients in RCTs comparing lithium with placebo.
Figure 2 Prevention of any episode in bipolar disorders patients in RCTs comparing lithium with placebo.
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Two studies (Weisler et al. 2011; Tohen et al. 2005) were
found that compared lithium to an atypical antipsychotic
(quetiapine and olanzapine, respectively). According to the
study inclusion criteria, we decided not to include an extra
review combining these two studies at this time.
Prior treatment stabilization
In one of the trials, all the participants were stabilized
on lithium treatment for unstated lengths of time prior
to randomization (Prien et al. 1973). In the study by
(Bowden et al. 2000), 34% of the group allocated to lith-
ium and 35% of the group allocated to placebo received
lithium as an open treatment prior to randomization. In
this study, lithium was discontinued gradually over two
weeks in those participants allocated to placebo.
In two studies (Calabrese et al. 2003; Bowden et al.
2003) for those patients continuing ongoing lithium dur-
ing the open-label phase, the dosage was tapered over at
least 3 weeks and discontinued a minimum of 1 week
prior to entering the double-blind phase of the study.
The studies followed participants from randomization
either until they experienced a mood episode or for
maximum periods of between 1 and 2 years.
The range of lithium levels employed was known for the
trials and the ranges targeted were all between 0.4 and 1.5.
mEq/l. In one trial, participants randomized to lithium
but with inadequate serum lithium monitoring (54 of 418)
were excluded from analysis (Weisler et al. 2011).
Five trials (Bowden et al. 2000; Calabrese et al. 2003;
Bowden et al. 2003; Weisler et al. 2011; Geddes et al.
2010) stated that they included participants who have
bipolar I disorder. Prien (Prien et al. 1973) required pa-
tients to have had a manic episode. Two trials included
participants with bipolar II disorder (Amsterdam and
Shults 2010; Kane et al. 1982).
Methodological quality of included studies
The more recent trials (Bowden et al. 2000; Calabrese
et al. 2003; Bowden et al. 2003; Weisler et al. 2011) over-
come many of the methodological weaknesses of the older
trials of lithium that have been described in the past such
as lack of intention-to-treat analysis, masking of treatment
allocation, size, diagnosis, and discontinuation artifacts
(Burgess et al. 2001). However, the descriptions of the
method of treatment allocation procedures and allocation
concealment often remained inadequate.
Figure 5 Study completion in bipolar disorders patients in RCTs comparing lithium with placebo.
Figure 4 Discontinuation of study due to reasons other than a mood episode in bipolar disorders patients in RCTs comparing lithium
with placebo.
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Synthesis of results
Lithium versus placebo
Mood episode prevention
Data were available from all seven trials with a total of
1,580 participants. Lithium was found to be more effect-
ive than placebo in preventing new episodes in bipolar
disorders (fixed effect RR 0.61, 95% CI 0.54 to 0.68, I2
68%; test for overall effect p < 0.001; random effects RR
0.66, 95% CI 0.53 to 0.82, test for overall effect p < 0.001).
Although moderate to high statistical heterogeneity
was seen, the direction of effect was the same in all trials:
no trial was found that lithium is inferior to placebo
(Figure 2).
Data on relapses/recurrences into mania and depressive
episodes were available separately from six trials (1,375
participants). Lithium prevented manic/hypomanic epi-
sodes (fixed effect RR 0.49, 95% Cl 0.39 to 0.61, I2 25%;
test for overall effect p < 0.001; random effects RR 0.52,
95% CI 0.38 to 0.71, test for overall effect p < 0.001).
Lithium prevented depressive episodes in a fixed effect
analysis (fixed effect RR 0.73, 95% CI 0.60 to 0.88, I2 49%;
test for overall effect p < 0.001). Random effects analysis
just failed to reach conventional statistical significance
(random effects RR 0.78, 95% CI 0.59 to 1.03, test for
overall effect p = 0.08). Heterogeneity was not statistically
significant in these analyses (Figure 3).
Discontinuation of treatment due to reasons other than a
mood episode
There were significantly more dropouts - discontinuation
for reasons other than mood episode - in those treated with
lithium compared to placebo (fixed effect RR 1.32, 95% CI
1.12 to 1.56; I2 23%, test for overall effect p = 0.001; random
effects RR 1.33, 95% CI 1.07 to 1.65, test for overall effect
p = 0.01) (Figure 4).
Study completion
Significantly, more patients completed the trials without
an episode or drop out in the group receiving lithium
compared with placebo (fixed effect RR 1.69, 95% CI
1.45 to 1.98, I2 69%, test for overall effect p < 0.001; random
effects RR 1.69, 95% CI 1.12 to 2.55, test for overall effect
p = 0.01) (Figure 5).
Lithium versus anticonvulsants
Mood episode prevention
There was available data from seven trials (1,305 parti-
cipants). Fewer participants on lithium relapsed than on
Figure 7 Prevention of depressive/manic episodes in bipolar disorders patients in RCTs comparing lithium with anticonvulsants.
Figure 6 Prevention of any episode in bipolar disorders patients in RCTs comparing lithium with anticonvulsants.
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anticonvulsant, although the difference did not meet
conventional levels of statistical significance in either
fixed effect (RR 0.90, 95% CI 0.80 to 1.02, I2 0%, test for
overall effect p = 0.10) or random effects analysis (ran-
dom effects RR 0.89, 95% CI 0.79 to 1.01, test for overall
effect p = 0.07). Heterogeneity was not significant
(Figure 6).
Data for manic and depressive episodes separately
were available from five of the seven trials, (n = 941).
Lithium showed significant superiority over anticonvul-
sants in the prevention of manic episodes (fixed effect
RR 0.68, 95% CI 0.50 to 0.92, I2 41%, test for overall
effect p = 0.01, random effects RR 0.66, 95% CI 0.44 to
1.00, test for overall effect p = 0.05). There was no sig-
nificant difference between lithium and anticonvulsant
in the prevention of depressive episode (fixed effect RR
1.16, 95% CI 0.92 to 1.45, I2 0%, test for overall effect
p = 0.20, random effects RR 1.15, 95% CI 0.92 to 1.43,
test for overall effect p = 0.23) (Figure 7).
Discontinuation of treatment due to reasons other than a
mood episode
Data for discontinuation for reasons other than a mood
episode were available from six studies (n = 1,085).
There was significant heterogeneity (I2 62.6%, p = 0.02),
and no significant difference between lithium and anti-
convulsants was found (fixed effect RR 1.17, 95% CI 0.99
to 1.39, I2 63%, test for overall effect p = 0.07, random
effects RR 1.19, 95% CI 0.87 to 1.63, test for overall
effect p = 0.27) (Figure 8).
Study completion
There was no significant difference in the number of
completers (fixed effect RR 0.93, 95% CI 0.76 to 1.14, I2
70%, test for overall effect p = 0.50, random effects RR
0.92, 95% CI 0.63 to 1.35, test for overall effect p = 0.67)
(Figure 9).
Discussion
Summary of evidence
This systematic review shows that treatment with lithium
decreases the probability of mood episodes compared to
placebo for up to 2 years in patients with bipolar disorders.
The treatment effect is present for prevention of both
manic relapse/recurrence and depressive relapse/recur-
rence, with the statistical significance of the latter finding
dependent on the type of analysis performed. The total
number of participants has increased substantially over the
past decade, and the more recent trials overcome many of
the shortcomings of earlier trials. In the analysis of overall
mood episode rates, there was evidence of statistically sig-
nificant heterogeneity between trials, but no single trial
found lithium to be less effective than placebo.
In all of the included trials except Prien et al. (1973)
and Geddes et al. (2010), data from patients who devel-
oped a mood episode were censored from the analysis of
time to discontinuation for reasons other than a mood
Figure 9 Study completion in bipolar disorders patients in RCTs comparing lithium with anticonvulsants.
Figure 8 Discontinuation of study due to reasons other than a mood episode in bipolar disorders patients in RCTs comparing lithium
with anticonvulsants.
Severus et al. International Journal of Bipolar Disorders 2014, 2:15 Page 13 of 17
http://www.journalbipolardisorders.com/content/2/1/15
episode (mutually exclusive endpoints). Similarly, data
from patients who developed a depressive episode were
censored from the analyses of time to a manic episode -
and vice versa. In contrast to Kaplan–Meier survival
analyses, in meta-analyses, with categorical data used for
analyses, censoring due to a mood episode may substan-
tially affect the risk of discontinuation due to reasons
other than a mood episode - and vice versa - if the drug
affects the risk of a mood episode compared to the risk
of dropping out due to reasons other than a mood epi-
sode differently than placebo. For lithium, this seems to
be the case. In our meta-analysis, significantly fewer
patients on lithium compared to placebo developed a
mood episode while at the same time, significantly more
patients on lithium compared to placebo dropped out of
the study due to reasons other than a mood episode. As-
suming that lithium’s prophylactic efficacy against mood
episodes were the primary event, more patients would
be at risk to potentially drop out for reasons other than
a mood episode (for example, due to side effects) - and
consequently, this meta-analysis may be biased to the
disadvantage of lithium when it comes to dropping out
of the study for reasons other than a mood episode.
Therefore, studying the number of individuals who
completed the study without dropping out for whatever
reasons (mood episodes + reasons other than a mood
episode) is not only clinically highly relevant - as lithium
can only work if patients adhere to it - but also essential
to get an unbiased picture on how lithium compares to
placebo in the long-term treatment of bipolar disorders.
In the present meta-analysis, lithium proved superior to
placebo in the number of individuals who completed
the study, thus confirming the results from the analyses
of mood episodes. However, there was significant quan-
titative heterogeneity.
Regarding the polarity of new mood episodes, the rela-
tive risk reduction of lithium appears more substantial
against manic episodes; however, the same limitations
which apply to data censoring due to mood episodes and
reasons other than a mood episode also apply in this case
(Licht and Severus 2014). In addition, the majority of pa-
tients in this meta-analysis were recruited with an index
manic episode which increases the likelihood of a manic
versus depressive recurrence/relapse - and therefore by
itself increases the probability of establishing prophylactic
antimanic versus antidepressant efficacy of a given drug,
all other relevant factors being equally distributed
(Calabrese et al. 2004). Therefore, lithium may even
perform better regarding depressive episodes than this
meta-analysis suggests. Furthermore, given the higher
absolute risk of depressive episodes (Judd et al. 2002),
lithium probably does protect against depression to a
clinically worthwhile degree, similar to recurrent unipolar
depression (Cipriani et al. 2006). When manic and
depressive episodes were considered separately, there was
no statistically significant heterogeneity between the trials.
Limitations
Limitations at study and outcome level
While this meta-analysis deals with the efficacy of
lithium to prevent mood episode in bipolar disorders, it
has to be said that the majority of the trials upon which
this meta-analysis is based primarily deals with patients
suffering from bipolar I disorder, with only two trials
exclusively enrolling patients with bipolar II disorder
(Amsterdam and Shults 2010; Kane et al. 1982) - and
two further including a small percentage of patients with
bipolar II disorder (Greil et al. 1997; Hartong et al.
2003). Therefore, our results primarily apply to patients
with bipolar I disorder.
To get an unbiased picture of lithium’s efficacy in the
long-term treatment of bipolar disorders, we decided to
exclude lithium discontinuation studies in which patients
with bipolar disorders who had been in remission on
lithium for at least 2 consecutive months before being
randomized to either continued lithium treatment or pla-
cebo/active comparator were selected (Coxhead et al.
1992; Melia 1968; Wolf et al. 1997). As a rule, patients
who have been in remission for at least 2 consecutive
months are generally believed to have recovered from the
index episode and enter prophylactic treatment (Grunze
et al. 2013; Tohen et al. 2009). Therefore, lithium discon-
tinuation studies may be enriched with patients respond-
ing to long-term treatment, in addition to tolerating
treatment with lithium. While this type of study may tend
to overestimate the efficacy of the enriched drug in
Kaplan-Meier survival analyses with respect to all patients
with bipolar disorders (Bowden et al. 2000; Gyulai et al.
2003), in meta-analyses, with categorical data used for
analyses, the consequences may be harder to predict (see
above). In addition, in the case of lithium, those random-
ized to placebo may be at an increased risk of a new
affective episode (Suppes et al. 1991; Suppes et al. 1993) if
lithium is rapidly discontinued following randomization
(Severus et al. 2008; Coxhead et al. 1992). While we ex-
cluded lithium discontinuation studies as described above,
we included studies enriched for tolerability to lithium
(Prien et al. 1973) or acute response/tolerability to other
agents (Calabrese et al. 2003; Bowden et al. 2003; Weisler
et al. 2011). Therefore, we cannot exclude some form of
bias in the comparison of lithium with lamotrigine,
though the respective studies were primarily enriched
for good tolerability to lamotrigine (Calabrese et al. 2003;
Bowden et al. 2003). Furthermore, we do not know
whether patients doing well on either quetiapine (Weisler
et al. 2011) or lamotrigine (Calabrese et al. 2003; Bowden
et al. 2003) will do better or less well on long-term lithium
treatment compared to an unselected sample of remitted
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patients with bipolar disorders. Lithium proved superior
to anticonvulsants in the prevention of manic episodes,
while there was no significant difference regarding the
prevention of depressive episodes, overall mood episodes,
drop-out for reasons other than a mood episode, or study
completers. However, the same limitations which applied
to the interpretation of mutually exclusive events dis-
cussed above with regard to lithium versus placebo also
apply. Nevertheless, the fact that lithium might do better
than anticonvulsants regarding manic episodes while there
was no significant difference regarding depressive episodes
may be related to lamotrigine being the alternative treat-
ment in three of the active comparator studies included in
our analyses (Licht et al. 2010; Calabrese et al. 2003;
Bowden et al. 2003). Lamotrigine has demonstrated its
efficacy (Calabrese et al. 2003; Bowden et al. 2003) and
has been granted approval in the European Union and
the US for the long-term treatment of (bipolar I) depres-
sive episodes and additional evidence being present for
acute antidepressant properties (Geddes et al. 2009). How-
ever, there is no evidence supporting its use in the acute
treatment of manic episodes and only limited evidence in
the long-term treatment of manic episodes (Goodwin
et al. 2004). Another issue which needs to be discussed is
that in two of the included studies, the study population
was exclusively enriched for patients being stable and
tolerating lamotrigine for a period of several weeks
(Calabrese et al. 2003; Bowden et al. 2003). While this
methodological approach may confer some benefit for
demonstrating efficacy in individual studies for the
enriched agent using Kaplan-Meier survival analyses
(Bowden et al. 2000; Gyulai et al. 2003), the consequences
in a meta-analytical approach may be harder to predict as
better tolerability may lead to fewer drop-outs due to
reasons other than a mood episode and eventually more
patients at risk to develop a mood episode. When we
analyzed the data separately for lithium versus lamotri-
gine (Licht et al. 2010; Calabrese et al. 2003; Bowden
et al. 2003), lithium was superior to lamotrigine in the
prevention of (hypo)manic episodes, while lamotrigine
did better than lithium in discontinuation for reasons
other than a mood episode, with no significant difference
between all other outcome parameter (data not shown).
Taken together, and similar to the acute treatment of
mania with anticonvulsants (Rosa et al. 2011), our data
argue against the idea of a class effect of anticonvulsants
in the prevention of depressive and manic episodes in
bipolar disorders. Finally, in two of the included studies,
the majority of patients had been on lithium in the past
before entering the trial - in contrast to the active
comparator (Calabrese et al. 2003; Bowden et al. 2003). As
previous use of lithium during a patient’s lifetime has been
found to be a risk factor for depressive episode (Severus
et al. 2010), it would be desirable to only include lithium-
naive patients in approval-seeking trials for a new com-
pound, if lithium is used as active comparator.
It is unclear how far lithium benefits unselected
patients with mood disorders in real-life clinical practice.
Some studies have found poorer outcomes in clinical
settings than would be anticipated from the results of
the randomized evidence (Markar and Mander 1989).
Some trials have attempted to replicate real-world condi-
tions in their choice of inclusion/exclusion criteria, use of
placebo, frequency of study visits, and lithium monitoring
(Geddes et al. 2010). However, it remains unknown to
what extent the results apply to the average clinical setting
because the percentage of patients approached for initial
evaluation of eligibility and those who participate in the
trials is not routinely reported (Toerien et al. 2009; Schulz
et al. 2010). Two important areas relating to the use of
lithium in patients with bipolar disorders in clinical prac-
tice are not addressed here since they have been recently
systematically reviewed elsewhere - prevention of suicide
and physical health effects. Taken together, the available
evidence shows that lithium is effective in the prevention
of suicide and death from all causes in patients with mood
disorders (Cipriani et al. 2013). Lithium use is associated
with increased risk of reduced urinary concentrating
ability, hypothyroidism, hyperparathyroidism, and weight
gain; however, there is little evidence for a clinically signifi-
cant reduction in renal function in most patients, and the
risk of end-stage renal failure is low (McKnight et al.
2012). Nevertheless, long-term safety has not been ade-
quately addressed in the studies upon which our meta-
analysis is based as the studies included only covered a
time span of up to 2 years. Finally, while our meta-analysis
formally deals with the prevention of mood episodes, in
studies where emergent mood episodes were the outcome
measure, some of those may not have reached full syndro-
mal criteria (Geddes et al. 2010). However, in clinical prac-
tice, the prevention of subsyndromal symptoms may be of
comparable importance, though the literature available
on this issue with regard to lithium is more limited (Frye
et al. 2006).
Limitations at review level
The results of this meta-analysis have to be interpreted
in the context of the methodology we used to conduct this
study - and which we described in detail in the ‘Methods’
section. For example, we limited our meta-analysis to
studies published either in English or German, although
only one study was excluded for reasons of language
(Figure 1). We employed the Cochrane Central Register
of Controlled Trials (CENTRAL) and a thorough strategy
to identify both published and unpublished studies, but it
remains possible that estimates of effect may be affected
by publication bias.
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Conclusions
In this meta-analysis, lithium is superior to placebo re-
garding prevention of overall mood episodes, manic
episodes, completion of study (no mood episode and no
drop out due to reasons other than a mood episode), and,
dependent on the type of analyses performed, depressive
episodes, while placebo is superior to lithium regarding
drop out due to reasons other than a mood episode. With
respect to the comparison with anticonvulsants, lithium is
superior regarding prevention of manic episodes; however
there is no significant difference regarding overall mood
episodes, depressive episodes, drop-out due to reasons
other than a mood episode, or study completion. With no
other drug available having such ample and consistent evi-
dence for its efficacy in the long-term treatment of bipolar
disorders, lithium remains the most valuable treatment
option in this indication (Miura et al. 2014).
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